624734-19-6

Basic information

• Product Name: 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDRO-
• Synonyms: 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDRO-;3-fluoro-tetrahydropyran-4-one;3-Fluorodihydro-2h-pyran-4(3h)-one;3-Fluorotetrahydro-4H-pyran-4-one;3-fluorooxan-4-one
• CAS NO: 624734-19-6
• Molecular Formula: C₅H₇FO₂
• Molecular Weight: 118.106
• Mol File: 624734-19-6.mol

Chemical Properties

• Boiling Point: 157℃
• Flash Point: 48℃
• Appearance: /
• Density: 1.15
• Vapor Pressure: 2.83mmHg at 25°C
• Refractive Index: 1.407
• CAS DataBase Reference: 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDRO-(624734-19-6)
• EPA Substance Registry System: 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDRO-(624734-19-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 624734-19-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDROis used as a key intermediate in organic synthesis for the development of various chemical compounds. Its unique structure and properties facilitate specific chemical reactions, contributing to the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDROis utilized as a building block for the design and synthesis of new pharmaceutical agents. Its potential pharmacological properties make it a promising candidate for the development of drugs targeting the central nervous system and as anti-inflammatory agents.
Used in Chemical Reactions:
4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDROis employed as a reactant in various chemical reactions due to its unique reactivity imparted by the fluorine atom. This allows for the formation of new compounds with specific properties, useful in different chemical applications.
Used in Drug Development:
4H-PYRAN-4-ONE, 3-FLUOROTETRAHYDROis used as a potential active pharmaceutical ingredient in drug development. Its pharmacological properties are being studied for the treatment of various conditions, particularly those related to the central nervous system and inflammation.

InChI:InChI=1/C5H7FO2/c6-4-3-8-2-1-5(4)7/h4H,1-3H2

Upstream product

• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 1149374-63-9 C₇H₁₃FO₃ 
• 28218-71-5 4,4-dimethoxytetrahydro-4H-pyran 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 104681-92-7 4,4-dimethoxytetrahydro-2H-pyran-3-ol 
• 693247-25-5 C₂₃H₂₉F₇N₂O₂ 
• 1630906-37-4 (3R,4R)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 
• 1630906-37-4 (3S,4S)-3-fluorotetrahydro-2H-pyran-4-amine hydrochloride 

Relevant articles and documents

SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (I) wherein HET is a group selected from among formulas (IIa) (IIb) (IIc) (IId) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases.

NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases

Enantioselective organocatalytic α-fluorination of cyclic ketones

The first highly enantioselective α-fluorination of ketones using organocatalysis has been accomplished. The long-standing problem of enantioselective ketone α-fluorination via enamine activation has been overcome via high-throughput evaluation of a new library of amine catalysts. The optimal system, a primary amine functionalized Cinchona alkaloid, allows the direct and asymmetric α-fluorination of a variety of carbo- and heterocyclic substrates. Furthermore, this protocol also provides diastereo-, regio-, and chemoselective catalyst control in fluorinations involving complex carbonyl systems.

Design, synthesis, and structure-activity relationship of novel CCR2 antagonists

A series of novel 1-aminocyclopentyl-3-carboxyamides incorporating substituted tetrahydropyran moieties have been synthesized and subsequently evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog 59 was found to posses potent antagonistic activity.